Bio Pharma Dive

JANUARY 6, 2024

The Emeryville, California- based gene therapy developer has several preclinical programs in development with Moderna, Ionis and Affini-T.

Gene Editing 214

Gene Editing Gene Gene Therapy Development 214

Fierce Pharma

JANUARY 6, 2024

A group of cell therapy experts, including CAR-T pioneers Drs. Bruce Levine and Carl June, wrote in support of continued use of CAR-T therapy.

Medicine 132

Medicine 132

Drug Patent Watch

JANUARY 6, 2024

This chart shows the drugs with the most patents in Philippines. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Philippines? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs 59

BioSpace

JANUARY 6, 2024

Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.

52

52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Fierce Pharma

JANUARY 6, 2024

Florida has secured a major win in its yearslong quest to import cheaper drugs from Canada—though the backlash from pharma trade groups on both sides of the border has been swift and fierce. | The FDA on Friday authorized Florida’s drug importation program, which will be valid for two years after it officially begins. The program quickly drew fire from pharma trade groups in both Canada and the United States.

Drugs 104

Drugs 104

BioSpace

JANUARY 6, 2024

In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.

52

52

BioSpace

JANUARY 6, 2024

Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.

Antibody 52

Antibody Development Drugs 52

BioSpace

JANUARY 6, 2024

The FDA’s calendar is relatively light in July, with only five major deadlines, including one for a PD-1 blocker and another for an opioid overdose drug.

Drugs 52

Drugs 52

BioSpace

JANUARY 6, 2024

Gilead Sciences’ blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space.

Antibody 52

Antibody Trials Drugs 52

BioSpace

JANUARY 6, 2024

Psychedelic drug developers are homing in on the potential $16 billion depression treatment market, with a particular focus on treatment-resistant depression.

Marketing 52

Marketing Development Drugs 52

Advertisement

Clinical Supply

BioSpace

JANUARY 6, 2024

Industry experts provide clinical trial design and protocol suggestions for psychedelic drug developers after an advisory committee voted against approving Lykos’ MDMA-assisted PTSD therapy.

Development 52

Development Drugs Clinical Trials Clinical Trials 52

BioSpace

JANUARY 6, 2024

Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson.

FDA Approval 40

FDA Approval Licensing Licensing Development 40